Will the UK government's COVID-19 dosing regime gamble pay off?
von Alison Dennis und Justyna Ostrowska
One Nucleus Genesis Digital 2020 – Key takeaways from our cell and gene therapy panel session
von Adrian Toutoungi
8+2+1 plus what? How UK data and market exclusivity rights will be affected from 1 January 2021
von Alison Dennis und Dr Paul England
Biologics and biosimilars litigation update
von Matthew Royle, Ph.D. und Dr. Nora E. Wessendorf, LL.M. (Washington)
SPC for ezetimibe/simvastatin considered invalid in preliminary relief proceedings
Targeted treatments – Part 3: the power of orphan drug protection
von Dr Paul England
German Federal Court of Justice invalidates Truvada SPC
Targeted treatments – Part 1: Targeted treatments: patents for particular populations
von Dr Paul England
Adrian Toutoungi, Josef Fuss and Matt Caskie discuss how biotech has managed its finances during the pandemic
von Adrian Toutoungi und Josef Fuss